-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

102.O1.6 102. Iron Homeostasis and Biology: Disorders of Iron and Heme and Novel Treatments Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Fundamental Science, Clinical Trials, Sickle Cell Disease, Biological, Adults, Translational Research, Non-Biological, Hematopoiesis, Animal Models, Clinical Research, Thalassemia, Clinically Relevant, Hemoglobinopathies, Diseases, Pediatric, Therapies, Biological Processes, Pathogenesis, Transfusion, Study Population
Monday, December 13, 2021: 4:30 PM-6:00 PM
B401-B402, Level 4, Building B (Georgia World Congress Center)
Moderators:
Karin E. Finberg, MD, PhD, Yale School of Medicine and Elizabeta Nemeth, PhD, University of California, Los Angeles
Disclosures:
Nemeth: Intrinsic LifeSciences: Consultancy; Silarus Pharma: Consultancy; Protagonist: Consultancy; Vifor: Consultancy; Ionis: Consultancy; Disc Medicine: Consultancy; Shield Therapeutics: Consultancy; AstraZeneca: Consultancy.
4:30 PM

Eduard J. Van Beers1*, Hanny Al-Samkari, MD2, Rachael F. Grace, MD3, Wilma Barcellini, MD4*, Andreas Glenthoej, MD5*, Malia P. Judge, BS6*, Penelope A. Kosinski, MS6*, Emily Xu, PhD6*, Vanessa Beynon, MD6*, Bryan McGee, PharmD, MBA6*, John B. Porter, MD, FRCP, FRCPath7* and Kevin H.M. Kuo, MD, MSc, FRCPC8

1Van Creveldkliniek Department of Internal Medicine, University Medical Center Utrecht, Utrecht, Netherlands
2Division of Hematology, Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard University, Cambridge, MA
3Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA
4Hematology Unit, Pathophysiology of Anemias Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
5Herlev University Hospital, Herlev, Denmark
6Agios Pharmaceuticals, Inc., Cambridge, MA
7Haematology Department, University College London Hospitals, London, United Kingdom, United Kingdom
8Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada

4:45 PM

Qingli Liu, PhD1*, Corbin Azucenas2*, Bryan Mackenzie, PhD2* and Mitchell Knutson, PhD3*

1University of Florida, Gainesville, FL
2University of Cincinnati College of Medicine, Cincinnati, OH
3University of Florida, HIGH SPRINGS, FL

5:00 PM

Xiuqi Li, PhD1, Larisa Lozovatsky, MS1*, Jackie A. Fretz, PhD2* and Karin E. Finberg, MD, PhD1

1Pathology, Yale School of Medicine, New Haven, CT
2Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT

5:15 PM

Vu Hong, PhD1, Sarah Ducamp, PhD2, Dean R Campagna, BS3*, Min Wu, PhD1*, Pavankumar N.G. Reddy, PhD1, Brian MacDonald, PhD, MBBChir, MRCP1*, Mark D. Fleming, MD, DPhil2, Maria G. Beconi, PhD, MS1* and Paul J Schmidt, PhD3

1Disc Medicine, Cambridge, MA
2Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA
3Department of Pathology, Boston Children's Hospital, Boston, MA

5:30 PM

Maciej W. Garbowski, MD PhD1*, Manuel Ugidos, PhD2*, Alberto Risueño, PhD2*, Rajasekhar N.V.S. Suragani, PhD3, Jeevan K. Shetty, MD FRCP4*, Sadanand Vodala, PhD5*, Anjan Thakurta, PhD6*, Martin Schwickart, PhD7* and John B. Porter, MD, FRCP, FRCPath1*

1UCL Cancer Institute Haematology Department, University College London, University College London Hospitals, London, United Kingdom
2BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Seville, Spain
3Acceleron Pharmaceuticals, Cambridge, MA
4Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
5Bristol Myers Squibb, Princeton, NJ
6Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ
7Formerly Bristol Myers Squibb, Princeton, NJ

5:45 PM

Mona Hamdy, MD1*, Amal El-Beshlawy, MD2, Fatma Soliman Elsayed Ebeid, MD3, Janet L. Kwiatkowski, MD, MSCE4,5, Julie Kanter, MD6, Baba PD Inusa, MD, MBBS7, Suzan Williams, MD8, David Lee, PhD9*, Noemi T Temin10*, Caroline Fradette, PhD9, Fernando Tricta, MD9 and Mohsen Saleh Elalfy, MD11

1Department of Pediatrics, School of Medicine, Cairo University, Cairo, Egypt
2Department of Pediatric Hematology, Pediatric Hospital of Cairo University, Sayeda Zeneb,Cairo, Egypt
3Pediatric Hematology/Oncology and BMT, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4Division of Hematology, Children's Hospital of Philadephia, Philadelphia, PA
5Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
6Division of Hematology and Oncology, Department of Medicine, University of Alabama-Birmingham, Birmingham, AL
7Paediatric Haematology, Evelina Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom
8Department of Haematology and Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
9Chiesi Canada Corporation, Toronto, ON, Canada
10Hematology/Immunology Program, Chiesi Rare Disease, Toronto, ON, Canada
11Pediatric Hematology/Oncology and BMT, Ain Shams University, Faculty of Medicine, Cairo, Egypt

*signifies non-member of ASH